Table 2.
Number of drug-disease interactions between drugs/drug classes recommended for each index condition and 11 other conditions in NICE guidelines. First line treatments are explicitly described as first line drugs or recommended for (almost) everyone with the condition; second line treatments (or other drugs) are explicitly described as second or third line drugs or recommended for only some subgroups or in some uncommon circumstances
| Index conditions | CKD (dose change) | CKD (avoid) | Heart failure | Depression | Type 2 diabetes | Atrial fibrillation | Osteoarthritis | COPD | Hypertension | Post MI | Dementia | Rheumatoid arthritis | Neuropathic pain | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes* | ||||||||||||||
| First line | 3 | 2 | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Second line | 11 | 11 | 5 | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27 |
| Depression† | ||||||||||||||
| First line | 1 | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Second line | 2 | 3 | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Heart failure‡ | ||||||||||||||
| First line | 2 | 1 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Second line | 3 | 4 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 |
*CG87 type 2 diabetes: first line: metformin, sulphonylurea, angiotensin converting enzyme inhibitors (ACEI), simvastatin/atorvastatin. Second line/other: angiotensin II receptor antagonists (ARB) for hypertension, calcium channel blocker for hypertension, diuretic for hypertension, α blocker for hypertension, β blocker for hypertension, K-sparing diuretic for hypertension, other statins (not simvastatin/atorvastatin), fibrate, erythromycin, phosphodiesterase type-5 inhibitors (PPDE5 inhibitors), metoclopramide, ezetemibe, omega-3 fish oil, domperidone, DPP-4 inhibitor/gliptin, thiazolidinedione, GLP-1 mimetic (exenatide), acarbose, insulin.
†CG90 depression: first line: selective serotonin reuptake inhibitors. Second line: venlafaxine, mirtazepine, duloxetine, reboxetine, flupenthixol, tryptophan, mianserin, tricyclic antidepressant (TCA), monoamine oxidase inhibitor (MAOI), moclobemide, lithium, antipsychotic (aripiprazole, olanzapine, quetiapine, risperidone).
‡CG108 heart failure: first line: ACEI, β blocker licensed for heart failure. Second line/other: licensed aldosterone antagonist, digoxin, ARB, hydralazine, nitrate, loop diuretic, warfarin, amlodipine if comorbid hypertension/angina, aspirin if comorbid coronary heart disease.